Sibi Biotech

Sibi Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, long-acting protein therapeutics. Based in Suzhou, China, the company utilizes its proprietary protein engineering platforms to create next-generation biologics with enhanced efficacy and safety profiles. Its primary research areas include oncology, where it develops optimized cytokines like IL-2 and IL-15, and metabolic diseases, focusing on long-acting hormones for diabetes and obesity. Sibi Biotech aims to address significant unmet medical needs by transforming short-acting proteins into potent, long-lasting treatments. The company's lead program, SIBI-001, is currently in clinical trials for various solid tumor indications.